Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» OREXQ's 30-Y Financials

Financials (Next Earnings Date: 2019-05-09 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

OREXQ Guru Trades in

OREXQ Guru Trades in

Q1 2018

OREXQ Guru Trades in Q1 2018

Seth Klarman 2,226,839 sh (unchged)
» More
Q2 2018

OREXQ Guru Trades in Q2 2018

Seth Klarman Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with OREXQ

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

Guru Date Action
Impact Price Range
(Average)*
Change from Average Comment Current Shares
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Orexigen Therapeutics Inc does not have enough historical financial data to display Peter Lynch Chart.

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:XSAT:DBP B, BOM:539287, BOM:531541, TSXV:VANC, XSAT:ACUC, BOM:523144, OTCPK:RSPI, BOM:524396, TSXV:LBL, OTCPK:SBFM, OTCPK:NBGV, BOM:524703, XCNQ:BUDD, BOM:533157, NSE:PARABDRUGS, BOM:530313, TSXV:GROW, BOM:538965, XCNQ:JUJU.A, BOM:540686 » details
Traded in other countries:JXS1.Germany,
Headquarter Location:USA
Orexigen Therapeutics Inc is an emerging pharmaceutical company. The company is developing neuroscience drugs that will ultimately address obesity and weight related medical issues.

Orexigen is an emerging pharmaceutical company, focusing on developing neuroscience drugs. The company screens older drugs seeking synergistic actions. The company's most advanced drug candidates target obesity.

Top Ranked Articles about Orexigen Therapeutics Inc

Seth Klarman Dives Into Orexigen in Wake of Sale Beleaguered pharmaceutical company is being acquired for $75 million
Baupost Group’s Seth Klarman (Trades, Portfolio) disclosed this week he plunged into floundering pharmaceutical company Orexigen Therapeutics Inc. (OREX) on April 13, buying over 7 million shares. Read more...
Orexigen Therapeutics, Inc. Plans For Near-term Sale Using Structured Process Through Chapter 11 Of U.S. Bankruptcy Code

Ratios

vs
industry
vs
history

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history

More Statistics

Revenue (TTM) (Mil) $75.29
EPS (TTM) $ -9.71
Beta7.39
Volatility288.87%
52-Week Range $0.00 - 1.60
Shares Outstanding (Mil)4.72

Analyst Estimate

Dec18
Revenue (Mil $)
EBIT (Mil $)
EBITDA (Mil $)
EPS ($) -3.54
EPS without NRI ($) -3.54
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: ----
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAN
Lower Leverage yoyN
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}